Logo image of BLPH

BELLEROPHON THERAPEUTICS INC (BLPH) Stock Fundamental Analysis

NASDAQ:BLPH - Nasdaq - US0787713009 - Common Stock - Currency: USD

0.1025  -0.28 (-73.39%)

After market: 0.114 +0.01 (+11.22%)

Fundamental Rating

2

Taking everything into account, BLPH scores 2 out of 10 in our fundamental rating. BLPH was compared to 551 industry peers in the Biotechnology industry. While BLPH seems to be doing ok healthwise, there are quite some concerns on its profitability. BLPH does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BLPH has reported negative net income.
In the past year BLPH has reported a negative cash flow from operations.
BLPH had negative earnings in 4 of the past 5 years.
In the past 5 years BLPH always reported negative operating cash flow.
BLPH Yearly Net Income VS EBIT VS OCF VS FCFBLPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 -10M -20M -30M -40M -50M

1.2 Ratios

BLPH's Return On Assets of -110.28% is on the low side compared to the rest of the industry. BLPH is outperformed by 81.59% of its industry peers.
BLPH has a worse Return On Equity (-220.54%) than 74.63% of its industry peers.
Industry RankSector Rank
ROA -110.28%
ROE -220.54%
ROIC N/A
ROA(3y)-121.74%
ROA(5y)-90.23%
ROE(3y)-309.79%
ROE(5y)-245.24%
ROIC(3y)N/A
ROIC(5y)N/A
BLPH Yearly ROA, ROE, ROICBLPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 500 -500 1K 1.5K 2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BLPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BLPH Yearly Profit, Operating, Gross MarginsBLPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022

More info and screens

5

2. Health

2.1 Basic Checks

BLPH has more shares outstanding than it did 1 year ago.
BLPH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BLPH Yearly Shares OutstandingBLPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2M 4M 6M 8M
BLPH Yearly Total Debt VS Total AssetsBLPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -34.54, we must say that BLPH is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of BLPH (-34.54) is worse than 94.86% of its industry peers.
BLPH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -34.54
ROIC/WACCN/A
WACCN/A
BLPH Yearly LT Debt VS Equity VS FCFBLPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M -40M

2.3 Liquidity

BLPH has a Current Ratio of 2.00. This indicates that BLPH is financially healthy and has no problem in meeting its short term obligations.
BLPH has a worse Current ratio (2.00) than 81.92% of its industry peers.
BLPH has a Quick Ratio of 2.00. This indicates that BLPH is financially healthy and has no problem in meeting its short term obligations.
BLPH has a Quick ratio of 2.00. This is amonst the worse of the industry: BLPH underperforms 80.43% of its industry peers.
Industry RankSector Rank
Current Ratio 2
Quick Ratio 2
BLPH Yearly Current Assets VS Current LiabilitesBLPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

BLPH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 38.27%, which is quite impressive.
EPS 1Y (TTM)38.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BLPH will show a very strong growth in Earnings Per Share. The EPS will grow by 22.86% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y50.96%
EPS Next 2Y5.24%
EPS Next 3Y39.61%
EPS Next 5Y22.86%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BLPH Yearly Revenue VS EstimatesBLPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
BLPH Yearly EPS VS EstimatesBLPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60 -80 -100

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BLPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BLPH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BLPH Price Earnings VS Forward Price EarningsBLPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BLPH Per share dataBLPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

BLPH's earnings are expected to grow with 39.61% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.24%
EPS Next 3Y39.61%

More info and screens

0

5. Dividend

5.1 Amount

BLPH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BELLEROPHON THERAPEUTICS INC

NASDAQ:BLPH (10/13/2023, 8:00:02 PM)

After market: 0.114 +0.01 (+11.22%)

0.1025

-0.28 (-73.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2023-08-14/amc
Earnings (Next)11-13 2023-11-13/bmo
Inst Owners0.13%
Inst Owner Change0%
Ins Owners192.64%
Ins Owner Change0%
Market Cap1.25M
Analysts43.33
Price Target2.04 (1890.24%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)77.72%
Min EPS beat(2)1.96%
Max EPS beat(2)153.48%
EPS beat(4)3
Avg EPS beat(4)39.59%
Min EPS beat(4)-8.25%
Max EPS beat(4)153.48%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.53%
EPS NY rev (1m)0%
EPS NY rev (3m)28.57%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-21.45%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.22
P/FCF N/A
P/OCF N/A
P/B 0.22
P/tB 0.22
EV/EBITDA N/A
EPS(TTM)-1.21
EYN/A
EPS(NY)-1.86
Fwd EYN/A
FCF(TTM)-0.9
FCFYN/A
OCF(TTM)-0.9
OCFYN/A
SpS0.46
BVpS0.46
TBVpS0.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -110.28%
ROE -220.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-121.74%
ROA(5y)-90.23%
ROE(3y)-309.79%
ROE(5y)-245.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2
Quick Ratio 2
Altman-Z -34.54
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.33%
EPS Next Y50.96%
EPS Next 2Y5.24%
EPS Next 3Y39.61%
EPS Next 5Y22.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y34.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y55.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.17%
OCF growth 3YN/A
OCF growth 5YN/A